


WHI-P154

Chemical Properties

CAS No. : 211555-04-3
 Formula: C₁₆H₁₄BrN₃O₃
 Molecular Weight: 376.2
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.
Targets(IC50)	Apoptosis,EGFR,JAK,Src,VEGFR
In vitro	The in vitro anti-glioblastoma activity of WHI-P154 was amplified > 200-fold and was selective by binding to recombinant human-derived epidermal growth factor. WHI-P154 inhibited STAT1 activation, iNOS expression and NO production in macrophages in vitro. WHI-P154 was shown to inhibit other common kinases, including EGFR, Src, Abl, VEGFR, MAPK and PI3-K, and induced apoptosis in human glioblastoma cell lines.WHI-P154 inhibited the adhesion and migration of glioblastoma cells in the ECM. WHI-P154 was significantly cytotoxic to human malignant glioma cell lines U373 and U87, causing apoptotic cell death at micromolar concentrations.
In vivo	The in vitro anti-glioblastoma activity of WHI-P154 was amplified > 200-fold and was selective by binding to recombinant human-derived epidermal growth factor. WHI-P154 inhibited STAT1 activation, iNOS expression and NO production in macrophages in vitro. WHI-P154 was shown to inhibit other common kinases, including EGFR, Src, Abl, VEGFR, MAPK and PI3-K, and induced apoptosis in human glioblastoma cell lines.WHI-P154 inhibited the adhesion and migration of glioblastoma cells in the ECM. WHI-P154 was significantly cytotoxic to human malignant glioma cell lines U373 and U87, causing apoptotic cell death at micromolar concentrations.
Kinase Assay	Kinase assays: WHI-P154 is tested in kinase assays. The panel of kinases is selected to broadly cover the kinome, providing a good approximation of specificity. For all kinases, recombinant rat (IKKβ) or human (all others), full-length or GST-kinase domain fusion proteins, are used. WHI-P154 is inactive (concentration that inhibits response by 50% [IC50] > 30 μM) for the following kinases: AKT, AuroraA, cdk2, cdk6, CHK1, FGFR1, GSK3b, IKKb, IKKi, INSR, MAPK1, MAPKAP-K2, MASK, MET, PAK4, PDK1, PKCb, ROCK1, TaoK3, TrkA.
Cell Research	Cells are seeded into a 96-well plate at a density of 2.5×10 ⁴ cells/well and incubated for 36 h at 37 °C before drug exposure. On the day of treatment, culture medium is carefully aspirated from the wells and replaced with fresh medium containing the quinazoline compounds WHI-P154 at concentrations ranging from 0.1 μM to 250 μM. Triplicate wells are used for each treatment. The cells are incubated with the compound for 24hours to 36hours at 37 °C in a humidified 5% CO ₂ atmosphere. To each

A DRUG SCREENING EXPERT

Cell Research	well, 10 μ L of MTT (final concentration, 0.5 mg/mL) is added, and the plate are incubated at 37 °C for 4 h. Than solubilized overnight at 37 °C in a solution containing 10% SDS in 0.01 M HCL. The absorbance of each well is measured in a microplate reader at 570 nm.(Only for Reference)
---------------	--

Solubility Information

Solubility	DMSO: 50 mg/mL (132.91 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.32 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6582 mL	13.2908 mL	26.5816 mL
5 mM	0.5316 mL	2.6582 mL	5.3163 mL
10 mM	0.2658 mL	1.3291 mL	2.6582 mL
50 mM	0.0532 mL	0.2658 mL	0.5316 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Changelian PS,Blood, 2008, 111(4), 2155-2157.

Narla RK, et al. Clin Cancer Res, 1998, 4(10), 2463-2471.

Narla RK, et al. Clin Cancer Res, 1998, 4(6), 1405-1414.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481